PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy
The present invention relates to novel antibody compositions for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
1. An isolated monoclonal antibody or a fragment thereof that binds to at least two different human inhibitory Killer Immunoglobulin-Like Receptor (KIR) receptor gene products, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of natural killer (NK) cell cytotoxicity in NK cells expressing at least one of said two different human inhibitory KIR receptors with the proviso that said isolated antibody or fragment thereof is not NKVFS1 or a fragment thereof, and further wherein said monoclonal antibody or fragment thereof is selected from the following:
a) the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224;
b) a chimeric antibody comprising the complementarity determining regions (CDRs) of the DF200 antibody;
c) a humanized antibody comprising the CDRs of the DF200 antibody; and
d) an Fab, F(ab′) 2 , Fab′, Fab′-SH, or scFv fragment of any one of the antibodies set forth in a), b) or c).
2. The isolated monoclonal antibody or a fragment thereof according to claim 1 , wherein said antibody is the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I -3224.
3. The isolated monoclonal antibody or a fragment thereof according to claim 1 , wherein said fragment is an Fab, F(ab′) 2 , Fab′, Fab′-SH, or scFv fragment of the DF200 antibody.
4. The isolated monoclonal antibody or a fragment thereof according to claim 1 , wherein said antibody is a chimeric antibody according to b) and further wherein said chimeric antibody comprises the entire variable regions of the DF200 antibody.
5. The isolated monoclonal antibody or a fragment thereof according to claim 4 , wherein said fragment is an Fab, F(ab′) 2 , Fab′, Fab′-SH, or scFv fragment of said chimeric antibody.
6. The isolated monoclonal antibody or a fragment thereof according to claim 1 , wherein said antibody is a humanized antibody according to c) comprising the CDRs of the DF200 antibody.
7. The isolated monoclonal antibody or a fragment thereof according to claim 6 , wherein said fragment is an Fab, F(ab′) 2 , Fab′, Fab′-SH, or scFv fragment of said humanized antibody.
8. The isolated monoclonal antibody or fragment thereof according to claim 1 , wherein said monoclonal antibody or fragment thereof binds to KIR2DL1 and KIR2DL2/3.
9. An isolated monoclonal antibody or fragment thereof according to claim 1 , which is conjugated or covalently bound to a toxin, detectable moiety, or a solid support.
10. A composition suitable for human administration comprising a pharmaceutically acceptable excipient and a monoclonal antibody or a fragment thereof that binds to at least two different human inhibitory Killer Immunoglobulin-Like Receptor (KIR) gene products, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity in NK cells expressing at least one of said two different human inhibitory KIR receptors with the proviso that said isolated antibody or fragment thereof is not NKVFS1 or a fragment thereof, and further wherein said monoclonal antibody or fragment thereof is selected from the following:
a) the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224;
b) a chimeric antibody or antibody fragment comprising the complementarity determining regions (CDRs) of the DF200 antibody;
c) a humanized antibody or antibody fragment comprising the CDRs of the DF200 antibody; and
d) an Fab, F(ab′) 2 , Fab′, Fab′-SH, or scFv fragment of any one of the antibodies set forth in a), b) or c).
11. The composition according to claim 10 , wherein said antibody is the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224.
12. The composition according to claim 10 , wherein said antibody is a chimeric antibody according to b) and further wherein said chimeric antibody comprises the entire variable regions of the DF200 antibody.
13. The composition according to claim 10 , wherein said fragment in b) is an Fab or F(ab′) 2 fragment of said chimeric antibody.
14. The composition according to claim 10 , wherein said antibody is a humanized antibody or antibody fragment according to c) comprising the CDRs of the DF200 antibody.
15. The composition according to claim 14 , wherein said fragment in c) is an Fab or F(ab′) 2 fragment of said humanized antibody.
16. The composition according to claim 10 , wherein said monoclonal antibody or fragment thereof binds to KIR2DL1 and KIR2DL2/3.
17. An isolated human, humanized or chimeric monoclonal antibody or a fragment thereof that binds to Killer Immunoglobulin-Like Receptors (KIRs) KIR2DL1 and KIR2DL2/3, with the proviso that said antibody or said fragment is not NKVFS1 or a fragment thereof, and further wherein said human, humanized or chimeric antibody or fragment thereof inhibits binding of HLA-C molecules to KIR2DL1 and KIR2DL2/3 and, thus, is capable of neutralizing or inhibiting KIR-mediated inhibition of natural killer (NK) cell cytotoxicity by NK cells expressing any of the following (i) KIR2DL1, (ii) KIR2DL2/3, and (iii) a combination of KIR2DL1 and KIR2DL2/3.
18. A composition suitable for human administration comprising a pharmaceutically acceptable excipient and a human, humanized or chimeric antibody or fragment thereof according to claim 17 .
19. An isolated human, humanized or chimeric monoclonal antibody or a fragment thereof that binds to Killer Immunoglobulin-Like Receptors (KIRs) KIR2DL1 and KIR2DL2/3, wherein said antibody or fragment thereof inhibits binding of HLA-C molecules to KIR2DL1 and KIR2DL2/3 and, thus, is capable of neutralizing or inhibiting KIR-mediated inhibition of natural killer (NK) cell cytotoxicity in NK cells expressing any of the following (i) KIR2DL1, (ii) KIR2DL2/3, and (iii) a combination of KIR2DL1 and KIR2DL2/3, wherein said human, humanized or chimeric monoclonal antibody or fragment thereof competes for binding to said KIR2DL1 on the surface of an NK cell with antibody DF200 produced by the hybridoma deposited as CNCM I-3224, and wherein said antibody of fragment is not NKVFS1 or a fragment thereof.
20. A composition suitable for human administration comprising a pharmaceutically acceptable excipient and a human, humanized or chimeric antibody or fragment thereof according to claim 19 .
21. The isolated human, humanized or chimeric monoclonal antibody or fragment thereof according to claim 19 , wherein said HLA-C molecules are selected from Cw1, Cw2, Cw3, Cw4, Cw5, Cw6, an HLA-C molecule having a lysine residue at position 80, Cw7, Cw8, and an HLA-C molecule having an asparagine residue at position 80.
22. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 17 , which promotes lysis of matched or HLA compatible target cells by NK cells expressing KIR2DL1, KIR2DL2/3 or a combination thereof, wherein the target cells are not effectively lysed in the absence of the monoclonal antibody or fragment thereof.
23. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 19 , which promotes lysis of matched or HLA compatible target cells by NK cells expressing KIR2DL1, KIR2DL2/3 or a combination thereof, wherein the target cells are not effectively lysed in the absence of the monoclonal antibody or fragment thereof.
24. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 22 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw1, Cw2, Cw3, Cw4, Cw5, Cw6, an HLA-C molecule having a lysine residue at position 80, Cw7, Cw8, an HLA-C molecule having an asparagine residue at position 80 and said binding is inhibited by said monoclonal antibody or fragment.
25. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 23 , wherein the NK cells in the absence of the monoclonal antibody or fragment thereof bind to at least one HLA-C molecule selected from Cw1, Cw2, Cw3, Cw4, Cw5, Cw6, an HLA-C molecule having a lysine residue at position 80, Cw7, Cw8, an HLA-C molecule having an asparagine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.
26. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 24 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw1, Cw3, Cw7, Cw8, and an HLA-C molecule having an asparagine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.
27. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 25 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw1, Cw3, Cw7, Cw8, and an HLA-C molecule having an asparagine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment thereof.
28. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 24 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw2, Cw4, Cw5, Cw6 and an HLA-C molecule having a lysine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.
29. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 25 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw2, Cw4, Cw5, Cw6 and an HLA-C molecule having a lysine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.
30. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 24 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw1, Cw3, Cw7, Cw8, and an HLA-C molecule having an asparagine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment, and said NK cells further bind to, in the absence of the monoclonal antibody or fragment, at least one HLA-C molecule selected from Cw2, Cw4, Cw5, Cw6 and an HLA-C molecule having a lysine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.
31. The isolated human, humanized or chimeric monoclonal antibody or a fragment thereof according to claim 25 , wherein the NK cells in the absence of the monoclonal antibody or fragment bind to at least one HLA-C molecule selected from Cw1, Cw3, Cw7, Cw8, and an HLA-C molecule having an asparagine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment, and said target cells further bind to, in the absence of the monoclonal antibody or fragment, at least one HLA-C molecule selected from Cw2, Cw4, Cw5, Cw6 and an HLA-C molecule having a lysine residue at position 80, and said binding is inhibited by said monoclonal antibody or fragment.